Abstract
刘安,王茜,叶江竹,孙丽君.暴露前预防:探索适合中国的HIV预防策略[J].Chinese journal of Epidemiology,2021,42(2):357-363
暴露前预防:探索适合中国的HIV预防策略
Pre-exposure prophylaxis: Exploring suitable HIV prevention strategies for China
Received:April 23, 2020  
DOI:10.3760/cma.j.cn112338-20200423-00628
KeyWord: 艾滋病病毒  暴露前预防  富马酸替诺福韦二吡呋酯  丙酚替诺福韦
English Key Word: HIV  Pre-exposure prophylaxis  Tenofovir disoproxil fumarate  Tenofovir alafenamide
FundProject:
Author NameAffiliationE-mail
Liu An Center for Infections Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China  
Wang Xi Center for Infections Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China  
Ye Jiangzhu Center for Infections Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China  
Sun Lijun Center for Infections Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China sunlijunkity@163.com 
Hits: 3637
Download times: 1504
Abstract:
      暴露前预防(PrEP)是国际指南推荐预防HIV感染的主要方式之一,在我国受到越来越多的关注。2019年,恩曲他滨联合丙酚替诺福韦(F/TAF)在美国获批成为继恩曲他滨联合富马酸替诺福韦二吡呋酯(F/TDF)后,第二个可用于PrEP的药物。本文结合最新国际指南、PrEP临床研究数据和我国实际情况,讨论PrEP在我国临床运用中的考量和挑战,并对提高PrEP认知、可及性、可负担性及用药依从性提出具体建议。
English Abstract:
      Pre-exposure prophylaxis (PrEP) is one of the main methods recommended by international guidelines for preventing HIV infection, and increasing attention has been paid to it in China. In 2019, emtricitabine/tenofovir alafenamide (F/TAF) was approved by the US FDA as the second PrEP option besides emtricitabine/tenofovir disoproxil fumarate (F/TDF). This article reviews the latest international guideline recommendations on PrEP, and the relevant clinical study data, discusses the considerations and challenges in implementing PrEP in the context of clinical practice in China, and provides suggestions for improving the awareness, accessibility, affordability and adherence of PrEP.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close